Sean A. McCarthy - Sep 20, 2023 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
CEO, Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
Stock symbol
CTMX
Transactions as of
Sep 20, 2023
Transactions value $
-$18,987
Form type
4
Date filed
9/22/2023, 07:13 PM
Previous filing
May 23, 2023
Next filing
Dec 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Award $0 +40K +9.87% $0.00 445K Sep 20, 2023 Direct F1, F2
transaction CTMX Common Stock Sale -$19K -14.6K -3.28% $1.30 431K Sep 22, 2023 Direct F2, F3
holding CTMX Common Stock 93.2K Sep 20, 2023 See footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The second milestone vesting condition was determined to be satisfied upon which the remaining 50% of the PSUs vested.
F2 Includes 161,250 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.
F4 Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.